G.Barekat Pharm (XTEH:BRKT1) Total Assets : IRR34,818,314 Mil (As of Mar. 2017)

View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Total Assets?

G.Barekat Pharm's Total Assets for the quarter that ended in Mar. 2017 was IRR34,818,314 Mil.

Total Assets is connected with ROA %. G.Barekat Pharm's annualized ROA % for the quarter that ended in Mar. 2017 was 3.00%. Total Assets is also linked to Revenue through Asset Turnover. G.Barekat Pharm's Asset Turnover for the quarter that ended in Mar. 2017 was 0.59.

G.Barekat Pharm Total Assets Historical Data

The historical data trend for G.Barekat Pharm's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Total Assets Chart

G.Barekat Pharm Annual Data

Trend

Mar16

Mar17

Total Assets

34,818,314.00

G.Barekat Pharm Semi-Annual Data
	Mar16	Mar17
Total Assets	-	34,818,314.00

G.Barekat Pharm Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

G.Barekat Pharm's Total Assets for the fiscal year that ended in Mar. 2017 is calculated as

Total Assets	=	Total Equity (A: Mar. 2017 )	+	Total Liabilities (A: Mar. 2017 )
	=	10564702	+	24253612
	=	34,818,314

G.Barekat Pharm's Total Assets for the quarter that ended in Mar. 2017 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2017 )	+	Total Liabilities (Q: Mar. 2017 )
	=	10564702	+	24253612
	=	34,818,314

G.Barekat Pharm (XTEH:BRKT1) Total Assets Explanation

Total Assets is connected with ROA %.

G.Barekat Pharm's annualized ROA % for the quarter that ended in Mar. 2017 is

ROA %	=	Net Income (Q: Mar. 2017 )	/	( (Total Assets (Q: Mar. 2016 )	+	Total Assets (Q: Mar. 2017 ))	/ count )
	=	1044706	/	( (0	+	34818314)	/ 1 )
	=	1044706	/	34818314
	=	3.00 %

Note: The Net Income data used here is one times the annual (Mar. 2017) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

G.Barekat Pharm's Asset Turnover for the quarter that ended in Mar. 2017 is

	Asset Turnover
=	Revenue (Q: Mar. 2017 )	/	( (Total Assets (Q: Mar. 2016 )	+	Total Assets (Q: Mar. 2017 ))	/ count )
=	20679266	/	( (0	+	34818314)	/ 1 )
=	20679266	/	34818314
=	0.59

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

G.Barekat Pharm Total Assets Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

G.Barekat Pharm (XTEH:BRKT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN

Website

http://www.bpharmed.com

G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines